Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0378-6323.171008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bilateral Choroidal Metastases from Primary Cutaneous Melanoma Following Nivolumab Discontinuation: A Case Report.
Ocul Immunol Inflamm
January 2025
Ocular Oncology Service, Institute of Oncology, Tecnologico de Monterrey, Monterrey, Mexico.
Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.
Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.
Advances in Cell and Immune Therapies for Melanoma.
Biomedicines
January 2025
Department of Hematology, Ion Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania.
The incidence rate of cutaneous melanoma is on the rise worldwide, due to increased exposure to UV radiation, aging populations, and exposure to teratogen agents. However, diagnosis is more precise, and the increased number of new cases is related to the improved diagnosis tools. Despite better early diagnosis and better therapies, melanoma has remained a significant public health challenge because of its aggressive behavior and high potential for metastasis.
View Article and Find Full Text PDFApplication of adoptive cell therapy in malignant melanoma.
J Transl Med
January 2025
Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employing immune cells with specific tumor-recognizing receptors, has emerged as a promising therapeutic approach to display on-tumor toxicity.
View Article and Find Full Text PDFPrimary cutaneous adenoid cystic carcinoma metastasising to the kidney.
BMJ Case Rep
January 2025
Urology, Barwon Health, Geelong, Victoria, Australia.
Adenoid cystic carcinoma (ACC) is a rare head and neck cancer; even more infrequently, it presents as a primary lesion at other sites. Due to ACC's usual pattern of perineural and perivascular spread, it often manifests in delayed local recurrence and distant metastases. Metastasis to the kidney is very rare with as few as 15 cases reported in the literature.
View Article and Find Full Text PDFAn overview of BAP1 biological functions and current therapeutics.
Biochim Biophys Acta Rev Cancer
January 2025
Havener Eye Institute, Department of Ophthalmology and Visual Science, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Division of Human Genetics, Department of Internal Medicine, The Ohio State University Columbus, OH 43210, USA. Electronic address:
BRCA1-associated protein 1 (BAP1) is a tumor suppressor gene that was first identified in 1998. Germline loss of functional variants in BAP1 is associated with a tumor predisposition syndrome with at least four cancers; uveal melanoma (UM), malignant mesothelioma (MMe), renal cell carcinoma (RCC), and cutaneous melanoma (CM). Furthermore, somatic BAP1 mutations are important drivers for several cancers most notably UM, MMe, RCC, intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!